Tyra Biosciences, Inc.
TYRA
$10.04
-$0.05-0.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 52.59% | 25.90% | 43.69% | 30.39% | 7.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.03% | 19.37% | 46.95% | 55.73% | 70.69% |
| Operating Income | -16.03% | -19.37% | -46.95% | -55.73% | -70.69% |
| Income Before Tax | -12.01% | -13.54% | -40.91% | -53.13% | -77.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.01% | -13.54% | -40.91% | -53.13% | -77.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.01% | -13.54% | -40.91% | -53.13% | -77.05% |
| EBIT | -16.03% | -19.37% | -46.95% | -55.73% | -70.69% |
| EBITDA | -15.93% | -19.25% | -46.98% | -55.78% | -70.94% |
| EPS Basic | 18.52% | 17.33% | -2.31% | -24.30% | -73.94% |
| Normalized Basic EPS | 18.52% | 17.35% | -2.26% | -24.33% | -73.97% |
| EPS Diluted | 18.52% | 17.33% | -2.31% | -24.30% | -73.94% |
| Normalized Diluted EPS | 18.52% | 17.35% | -2.26% | -24.33% | -73.97% |
| Average Basic Shares Outstanding | 37.46% | 37.34% | 37.75% | 23.20% | 1.80% |
| Average Diluted Shares Outstanding | 37.46% | 37.34% | 37.75% | 23.20% | 1.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |